Art. -Nr.: HY-16680

Helioxanthin 8-1

(Synonyms: Helioxanthin analogue 8-1)

2 Cited Publications

Kundenbewertung

Based on 2 publication(s) in Google Scholar

Helioxanthin 8-1(Helioxanthin analogue 8-1) is an anti-HBV agent. Helioxanthin 8-1 exhibits anti-hepatitis B virus activity in both in vitro human hepatitis B virus models and animal models. Helioxanthin 8-1 inhibits the synthesis of duck hepatitis B virus (DHBV) DNA, covalently closed circular DNA, RNA and proteins, thereby blocking DHBV replication. Helioxanthin 8-1 shows higher cytotoxicity in virus-induced cells than in non-induced cells. Helioxanthin 8-1 can be used in studies related to hepatitis B virus infection.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.0%
CAS. Nr.: 840529-13-7
Formel: C₂₀H₁₂N₂O₆
Molecular Weight:376.32

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Helioxanthin 8-1 Chemical Structure

CAS. Nr.: 840529-13-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
Chemical Information
Publications (2)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Cellular Effect

Cell Line	Type	Value	Description	References
HepG2	CC₅₀	29 μM Compound: 45505	Cytotoxicity against HBV transfected human HepG2 cells by MTT assay Cytotoxicity against HBV transfected human HepG2 cells by MTT assay	[PMID: 17488817]
HepG2	IC₅₀	>1 μM Compound: 45505	Inhibition of HBV promoter in human HepG2 cells by luciferase reporter gene assay Inhibition of HBV promoter in human HepG2 cells by luciferase reporter gene assay	[PMID: 17488817]
HepG2 2.2.15	IC₅₀	0.08 μM Compound: 8-1	Antiviral activity against HBV in ayw wild type HepG2(2.2.15) cells assessed as inhibition of viral DNA replication Antiviral activity against HBV in ayw wild type HepG2(2.2.15) cells assessed as inhibition of viral DNA replication	[PMID: 17488817]
HepG2 2.2.15	IC₅₀	0.3 μM Compound: 8-1	Antiviral activity against HBV in human HepG2(2.2.15) cells assessed as inhibition of viral pre-genomic RNA replication Antiviral activity against HBV in human HepG2(2.2.15) cells assessed as inhibition of viral pre-genomic RNA replication	[PMID: 17488817]
HepG2 2.2.15	IC₅₀	0.9 μM Compound: 8-1	Antiviral activity against HBV in human HepG2(2.2.15) cells assessed as inhibition of viral 2.4/2.1RNA replication Antiviral activity against HBV in human HepG2(2.2.15) cells assessed as inhibition of viral 2.4/2.1RNA replication	[PMID: 17488817]
HepG2 2.2.15	CC₅₀	9 μM Compound: 45505	Cytotoxicity against HBV transfected human ayw wild type HepG2(2.2.15) cells by MTT assay Cytotoxicity against HBV transfected human ayw wild type HepG2(2.2.15) cells by MTT assay	[PMID: 17488817]
HepG2 2.2.15	CC₅₀	9 μM Compound: 5	Cytotoxicity against human HepG2(2.2.15) cells assessed as reduction in cell viability after 3 days by methylene blue assay Cytotoxicity against human HepG2(2.2.15) cells assessed as reduction in cell viability after 3 days by methylene blue assay	[PMID: 28383274]

In Vitro

Helioxanthin 8-1 (0.1-3 μM; 6 days) potently inhibits DHBV replication in induced dstet5 cells, with an IC₅₀ value of 0.25 μM against viral DNA, 0.1 μM against viral RNA, and 0.1 μM against core protein. It also reduces cccDNA levels in a dose-dependent manner^[1].
Helioxanthin 8-1 (0.03-0.3 μM; 6 days, in combination with 3TC) exhibits additive anti-DHBV activity in dstet5 cells when used in combination with 3TC (HY-B0250). Enhanced viral DNA inhibition is observed across the combined concentration range, with a CI value of 0.82^[1].
Helioxanthin 8-1 (10-50 μM; 3 days) exhibits higher cytotoxicity towards virus-induced dstet5 cells (CC₅₀ = 18 μM) than towards uninduced dstet5 cells (CC₅₀ = 45 μM)^[1].
Helioxanthin 8-1 (100 μM; 48 h) reduces the viability of Vero cells (ATCC CCL-81) to 70.6%, with a CC₅₀ value of >100 μM^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[1]

Cell Line:

doxycycline-induced (viral replication active) and non-induced (no viral replication) dstet5 cells
Concentration:

10, 30, 50 μM
Incubation Time:

3 days (after 3 days of induction or non-induction)
Result:

Had a mean ± sd CC₅₀ of 18 μM in viral-induced dstet5 cells.
Had a mean ± sd CC₅₀ of 45 μM in non-induced dstet5 cells.

Cell Cytotoxicity Assay^[2]

Cell Line:

Vero cells (ATCC CCL-81)
Concentration:

100 μM
Incubation Time:

48 h
Result:

Reduced Vero cell viability to 70.6%.
Exhibited a CC₅₀ value of >100 μM.

Chemical Information

CAS. Nr. 840529-13-7
Appearance Solid
Molecular Weight 376.32
Formel C₂₀H₁₂N₂O₆
Color Light yellow to yellow
SMILES

O=C1NNC(C2=C(C3=CC=C(OCO4)C4=C3)C5=C6C(OCO6)=CC=C5C=C21)=O
Synonyms

Helioxanthin analogue 8-1
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (2)

All

Sort by:

Journal Impact Factor

Microorganisms

Antiviral Activity of Vacuolar ATPase Blocker Diphyllin against SARS-CoV-2. [Abstract]

2021 Feb 25;9(3):471. PMID: 33668694
ACS Infect Dis

Discovery of New Hepatitis B Virus Capsid Assembly Modulators by an Optimal High-Throughput Cell-Based Assay. [Abstract]

2019 May 10;5(5):778-787. PMID: 30761887

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 10 mg/mL (26.57 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.6573 mL

13.2866 mL

26.5731 mL

5 mM

0.5315 mL

2.6573 mL

5.3146 mL

10 mM

0.2657 mL

1.3287 mL

2.6573 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1 mg/mL (2.66 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 1 mg/mL (2.66 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Ying C, et al. Helioxanthin analogue 8-1 inhibits duck hepatitis B virus replication in cell culture. Antivir Chem Chemother. 2010;21(2):97-103. [Content Brief]

[2]. Stefanik M, et al. Antiviral Activity of Vacuolar ATPase Blocker Diphyllin against SARS-CoV-2. Microorganisms. 2021;9(3):471. Published 2021 Feb 25. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.6573 mL	13.2866 mL	26.5731 mL	66.4328 mL
	5 mM	0.5315 mL	2.6573 mL	5.3146 mL	13.2866 mL
	10 mM	0.2657 mL	1.3287 mL	2.6573 mL	6.6433 mL
	15 mM	0.1772 mL	0.8858 mL	1.7715 mL	4.4289 mL
	20 mM	0.1329 mL	0.6643 mL	1.3287 mL	3.3216 mL
	25 mM	0.1063 mL	0.5315 mL	1.0629 mL	2.6573 mL

Keywords

Helioxanthin 8-1

2 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Helioxanthin 8-1

Publications Citing Use of MedChemExpress (MCE) Helioxanthin 8-1

Biologische Aktivität

Chemical Information

Publications (2)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Helioxanthin 8-1 Related Classifications

HY-16680 Related Classifications